Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELPIDA Gene Therapy for Spastic Paraplegia Type 50 (SPG50)
NCT05518188Phase 2Recruiting
- Sponsor
- Elpida Therapeutics
- Start
- Feb 2023
- Primary completion
- Oct 2028
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MELPIDA in Spastic Paraplegia Type 50 (SPG50), sponsored by Elpida Therapeutics. Primary endpoint: Incidence of unanticipated treatment-related toxicities, Grade 3 or higher at 60 months. Started Feb 2023; status: recruiting.
02
Drugs
MELPIDA
03
Conditions
Spastic Paraplegia Type 50 (SPG50)
Beyond the preview
Go deeper on NCT05518188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518188.